Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $68.15, for a total value of $6,815,000.00. Following the transaction, the executive vice president directly owned 177,523 shares in the company, valued at approximately $12,098,192.45. The trade was a 36.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Hite also recently made the following trade(s):
- On Tuesday, September 22nd, Christopher Hite sold 100,000 shares of Royalty Pharma stock. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00.
Royalty Pharma Stock Down 0.0%
Shares of Royalty Pharma stock traded down $0.01 during midday trading on Wednesday, hitting $68.67. The company's stock had a trading volume of 3,192,451 shares, compared to its average volume of 3,426,408. Royalty Pharma PLC has a 1-year low of $37.31 and a 1-year high of $70.37. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $39.39 billion, a P/E ratio of 57.23, a PEG ratio of 1.36 and a beta of 0.37. The stock has a 50-day simple moving average of $61.77 and a 200-day simple moving average of $54.81.
Royalty Pharma Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. Royalty Pharma's dividend payout ratio (DPR) is 78.33%.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of RPRX. Renaissance Technologies LLC acquired a new stake in shares of Royalty Pharma in the 1st quarter valued at about $37,941,000. Bank of America Corp DE boosted its position in shares of Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company's stock worth $167,696,000 after buying an additional 786,921 shares during the period. Carmignac Gestion acquired a new position in shares of Royalty Pharma during the first quarter worth about $30,279,000. Congress Asset Management Co. bought a new stake in Royalty Pharma in the 3rd quarter valued at approximately $30,761,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in Royalty Pharma during the 3rd quarter worth approximately $24,225,000. Institutional investors and hedge funds own 54.35% of the company's stock.
Analyst Ratings Changes
RPRX has been the subject of a number of analyst reports. TD Cowen raised their price target on shares of Royalty Pharma from $68.00 to $80.00 and gave the stock a "buy" rating in a research note on Wednesday. Bank of America reiterated a "buy" rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Wall Street Zen raised Royalty Pharma from a "buy" rating to a "strong-buy" rating in a report on Saturday. Morgan Stanley increased their target price on Royalty Pharma from $65.00 to $67.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Finally, Citigroup raised their target price on Royalty Pharma from $70.00 to $78.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $65.00.
Get Our Latest Stock Report on Royalty Pharma
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.